Matinas BioPharma Holdings, Inc.
www.matinasbiopharma.comAI Executive Summary
AI-powered analysis of 10-Q filing content
Matinas BioPharma shows significant deterioration with cash declining 40% to $2.4M, zero R&D spending indicating halted drug development, and current liabilities exceeding current assets creating liquidity pressure. The company maintains $2.3M in IPR&D assets while generating no revenue and burning cash on administrative costs.
Red Flags Detected (6)
Cash and equivalents dropped 40% from $4.0M to $2.4M in one quarter
Zero R&D spending in Q1 2026 vs $85K in Q1 2025 - drug development appears halted
Current ratio deteriorated to 1.32 from 2.78 - liquidity concerns
3 more red flags detected
Key Takeaways
Company appears to be in financial distress with rapidly declining cash position
Business model viability questionable with no R&D activity for a biotech company
2 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.